Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies-Reference-Cited by-同舟云学术

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

Published:2020 Issue:6 Volume:10 Page:2645-2658
ISSN:1838-7640
Container-title:Theranostics
language:en
Short-container-title:Theranostics

Author:

Schriewer Levin,Schütze Kerstin,Petry Katharina,Hambach Julia,Fumey William,Koenigsdorf Julia,Baum Natalie,Menzel Stephan,Rissiek Björn,Riecken Kristoffer,Fehse Boris,Röckendorf Jana Larissa,Schmid Joanna,Albrecht Birte,Pinnschmidt Hans,Ayuk Francis,Kröger Nicolaus,Binder Mascha,Schuch Gunter,Hansen Timon,Haag Friedrich,Adam Gerhard,Koch-Nolte Friedrich,Bannas Peter

Publisher

Ivyspring International Publisher

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Medicine (miscellaneous)

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanobody‐based heavy chain antibodies and chimeric antibodies;Immunological Reviews;2024-08-30

2. Single domain Camelid antibody fragments for molecular imaging and therapy of cancer;Frontiers in Oncology;2023-09-08

3. Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab;American Journal of Clinical Pathology;2023-08-01

4. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors;Frontiers in Immunology;2022-11-02

5. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy;Frontiers in Immunology;2022-10-27